Adipotide

An experimental compound designed to kill the blood vessels feeding white fat tissue — targeted vascular destruction as a weight-loss strategy. The monkey studies that made it famous also documented kidney injury.

Adipotide (FTPP) works by an unusual and aggressive route: it is a peptide that homes to the blood vessels supplying white fat tissue and then triggers those vessels to die. Cutting off the blood supply causes the fat tissue itself to be resorbed. It is not a metabolic modifier — it destroys the vasculature of a tissue, which is why the animal fat loss was rapid and why the toxicity profile is what it is.

Rhesus monkey studies showed real fat loss. The identical papers document renal tubular damage — dose-dependent kidney injury was IN the headline research, not a later discovery. A small human oncology trial was registered years ago; no results have translated into any approval path.

• NONE for weight loss. There is no completed human trial supporting it for that use.
• The famous result is in obese rhesus monkeys, which lost substantial weight. That study also reported kidney toxicity, and renal injury has been the recurring finding across its development.
• A small human trial was initiated in prostate cancer patients, reflecting the compound's origin as an anti-tumour vascular-targeting agent rather than a weight-loss drug. It did not lead to approval or continued development for obesity.
• The kidney is the specific organ of concern — dose-limiting renal toxicity is the reason this compound is not a weight-loss drug, and no human exposure has been established that avoids it.
• Sold as research-chemical peptide supply of unverified identity and sterility.

Given by injection. Human pharmacokinetics are not adequately characterised outside the limited oncology work. The mechanism is inherently destructive to tissue vasculature rather than modulatory, which is why it does not behave like other weight-loss agents and why its toxicity is organ damage rather than tolerability.

Kidney toxicity is the documented, primary-source risk, and vascular ablation is not a reversible lever like appetite. The compound's own supporting literature carries its organ-damage signal.

• Everyone — a vascular-destroying peptide whose development was limited by kidney toxicity, with no human weight-loss evidence
• Most emphatically anyone with any kidney impairment
• Anyone taking nephrotoxic medication
• Anyone pregnant or breastfeeding

• Anything nephrotoxic — NSAIDs, some antibiotics, dehydration — compounds the specific risk this compound carries.
• No characterised human interaction profile exists.

• Kidney function is the concern this compound is defined by, and anyone using it outside a trial has no protocol behind them and no one interpreting the results.
• Reduced urine output, swelling, or any sign of kidney injury needs urgent assessment.
• Injection-site infection, given unverifiable sterility of research-chemical supply.

Nothing specific is established. The concern with a compound whose dose-limiting toxicity is organ damage is that stopping does not undo damage already done — anyone who used it and has symptoms suggesting kidney injury needs assessment rather than reassurance that it has left their system.

US: unapproved investigational compound.

• Fatty Liver/Adipose Tissue Dual-Targeting Nanoparticles with Heme Oxygenase-1 Inducer for Amelioration of Obesity, Obesity-Induced Type 2 Diabetes, and SteatohepatitisAdv Sci (Weinh) · 2022
• Prohibitin: targeting peptide coupled to ovarian cancer, luteinization and TGF-β pathwaysJ Ovarian Res · 2017
• A comparative study between nanoparticle-targeted therapeutics and bioconjugates as obesity medicationJ Control Release · 2013
• A peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeysSci Transl Med · 2011
• Comment on "a peptidomimetic targeting white fat causes weight loss and improved insulin resistance in obese monkeys"Sci Transl Med · 2012